Philogen S.P.A.
Records under this name other than the patents Philogen S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,390,666 | Vascular Endothelial Growth Factor/Anti-Fibronectin Antibody Fusion Proteins Lapsed on the fee record Ended Jul 19, 2026 · High confidence | Lapsed on the fee record | Ended Jul 19, 2026 | High confidence |
| US 8,679,488 | Targeting of Bone Marrow Neovasculature Lapsed on the fee record Ended Mar 25, 2026 · High confidence | Lapsed on the fee record | Ended Mar 25, 2026 | High confidence |
| US 8,481,684 | Novel Antigen Associated with the Neovasculature of Tumour Metastases Term ended Term ended Mar 7, 2026 · Medium confidence | Term ended | Term ended Mar 7, 2026 | Medium confidence |
| US 9,896,503 | Novel Antigen Associated with the Neovasculature of Tumour Metastases Term ended Term ended Mar 7, 2026 · Low confidence | Term ended | Term ended Mar 7, 2026 | Low confidence |
| US 8,455,625 | Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12 Lapsed on the fee record Ended Jun 4, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 4, 2025 | From the USPTO record |
| US 10,906,963 | Non-glycosylated anti-tenascin antibody Lapsed on the fee record Ended Feb 2, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 2, 2025 | From the USPTO record |
| US 9,549,981 | Sequential antibody therapy Lapsed on the fee record Ended Jan 24, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 24, 2025 | From the USPTO record |
| US 8,344,177 | Albumin binding molecules and uses thereof Formerly held Lapsed on the fee record Ended Jan 1, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 1, 2025 | From the USPTO record |
| US 9,527,907 | Antigens associated with endometriosis, psoriatic arthritis and psoriasis Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 10,858,411 | IL22 Immunoconjugates Lapsed on the fee record Ended Dec 8, 2024 · High confidence | Lapsed on the fee record | Ended Dec 8, 2024 | High confidence |